^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SDC2 (Syndecan 2)

    i
    Other names: SDC2, Syndecan 2, Fibroglycan 2, SYND2, Heparan Sulfate Proteoglycan 1 Cell Surface-Associated, Heparan Sulfate Proteoglycan Core Protein, Syndecan Proteoglycan 2, Syndecan-2, CD362, HSPG1, HSPG, Cell Surface-Associated Heparan Sulfate Proteoglycan 1, CD362 Antigen
    Associations

    News

    Trials
    1d
    Stool-based methylated syndecan-2 test and fecal immunochemical test for advanced colorectal neoplasia screening in the Chinese population: A multicenter randomized noncomparative study. (PubMed, Chin Med J (Engl))
    This study revealed the effectiveness of the mSDC2 test and FIT in detecting advanced colorectal neoplasia in a large Chinese population in a real-world setting, and indicated a possible improvement in adherence to colonoscopy for the mSDC2 test. Further studies with improved comparability and longer follow-up are warranted to clarify its clinical utility.
    Journal
    |
    SDC2 (Syndecan 2)
    11d
    Insect-Spinach Waste Synergy: Enhancing Cyamopsis tetragonoloba under Copper Stress. (PubMed, ACS Omega)
    Image analysis confirmed that callus morphology and growth were preserved, compared with the control. These results highlight the safe use of FHSPF2 and FHSPG1 NPs in agricultural biotechnology and biomedical applications, providing a sustainable approach to mitigate heavy metal stress and enhance plant resilience.
    Journal
    |
    SDC2 (Syndecan 2)
    23d
    Evaluating the cross-reactivity of a stool methylated syndecan-2 (meSDC2) test in colorectal cancer detection. (PubMed, J Gastrointest Oncol)
    The stool meSDC2 test demonstrated a high positivity rate in CRC but showed low positivity rates in other cancers, except in biliary tract cancer. This indicates that the stool meSDC2 test has a high specificity for CRC, as the results are minimally influenced by other cancer types.
    Journal
    |
    SDC2 (Syndecan 2)
    1m
    Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation. (PubMed, BMC Endocr Disord)
    Our findings suggest that SDC2 would be a promising therapy target for advanced radioiodine refractory thyroid cancer, but the role in PTC progression is complicated and requires further exploration.
    Journal
    |
    TJP1 (Tight Junction Protein 1) • SDC2 (Syndecan 2)
    2ms
    An Automated Multi-Sample Digital LAMP Platform for Quantitative Detection of SDC2 Methylation in Colorectal Cancer. (PubMed, Anal Chem)
    The results showed elevated SDC2 methylation was detected in tumor tissues across all CRC stages. This integrated automated dLAMP platform provides a robust, multisample high-throughput tool for methylation-based diagnostics and holds strong potential for noninvasive early cancer screening and clinical biomarker applications.
    Journal
    |
    SDC2 (Syndecan 2)
    3ms
    SDC2 and FN as cargo proteins in circulating extracellular vesicles in obese breast cancer patients with lymph node metastasis. (PubMed, Sci Rep)
    Bioinformatics analyses further confirmed the association of SDC2 and FN expression with BC staging and prognosis. These findings underscore the potential of circulating MV-enriched EV-associated SDC2 and FN, along with their tumor tissue mRNA expression, as potential predictive biomarkers for LNM and chemotherapy response in chemotherapy-naïve obese BC patients.
    Journal
    |
    SDC1 (Syndecan 1) • SDC4 (Syndecan 4) • SDC2 (Syndecan 2)
    3ms
    The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer. (PubMed, Cancers (Basel))
    Selected lncRNAs, including THOR and LINC01094, have also demonstrated significant prognostic value. Despite these advances, challenges persist, including inconsistent reporting, limited external validation, and a lack of replication by independent research groups.
    Review • Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MIR21 (MicroRNA 21) • GAS6 (Growth arrest specific 6) • MIR211 (MicroRNA 211) • IGFBP3 (Insulin-like growth factor binding protein 3) • LINC01094 (Long Intergenic Non-Protein Coding RNA 1094) • MIR140 (MicroRNA 140) • MIR150 (MicroRNA 150) • MIR215 (MicroRNA 215) • MIR675 (MicroRNA 675) • SDC2 (Syndecan 2) • SEPTIN9 (Septin 9) • SNHG14 (Small Nucleolar RNA Host Gene 14) • ASB16-AS1 (ASB16 Antisense RNA 1)
    3ms
    Syndecan-2 positively regulates Wnt/β-catenin signaling in breast cancer cells. (PubMed, Int J Biochem Cell Biol)
    Collectively, our results demonstrate that syndecan-2 is a positive regulator of canonical Wnt signaling. These results also suggest that syndecan-2 is a potential clinical target for inhibiting the progression of some human cancers.
    Journal
    |
    SDC2 (Syndecan 2)
    4ms
    Stool-based methylated syndecan-2 testing has a high positive predictive value in an average/increased-risk population: a multicenter retrospective study. (PubMed, Gastroenterol Rep (Oxf))
    The mSDC2 test, which has a high PPV for both ACN and CRC, is expected to be an alternative CRC screening strategy. Patients with a positive mSDC2 test might require a colonoscopy as soon as possible, even if the previous colonoscopy was negative.
    Retrospective data • Journal
    |
    SDC2 (Syndecan 2)
    4ms
    A randomized, open-label, multicenter clinical study comparing the combination of epalorlimovalizumab and bevacizumab with TAS-102 versus bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer (ChiCTR2500106797)
    P4, N=84, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GBP5 (Guanylate Binding Protein 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • APOE (Apolipoprotein E) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1) • GBP4 (Guanylate Binding Protein 4) • MX1 (MX Dynamin Like GTPase 1) • SDC2 (Syndecan 2)
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4ms
    Combined Methylation Analysis of SDC2 and TFPI2 in Plasma: A Noninvasive Liquid Biopsy Approach for Early Detection of Colorectal Polyp. (PubMed, Int J Mol Cell Med)
    For HRP, the AUC was 0.890 (95% CI 0.596 to 0.843, p<0.001) with a sensitivity of 70% (95% CI 51% - 84%) and specificity of 92% (95 CI 75% - 99%). The combined assessment of SDC2 and TFPI2 methylation presents a potential approach for the early non-invasive detection of CRC and its associated precancerous lesions.
    Journal • Liquid biopsy
    |
    SDC2 (Syndecan 2)